Suppliers and packagers for generic pharmaceutical drug: CYCLOSPORINE

CYCLOSPORINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Apotex	CYCLOSPORINE	cyclosporine	CAPSULE;ORAL	065040	ANDA	Apotex Corp.	60505-0133-0	30 CAPSULE, GELATIN COATED in 1 BOTTLE (60505-0133-0)	2002-05-29
Apotex	CYCLOSPORINE	cyclosporine	CAPSULE;ORAL	065040	ANDA	Apotex Corp.	60505-0134-0	30 CAPSULE, GELATIN COATED in 1 BOTTLE (60505-0134-0)	2002-05-29
Apotex	CYCLOSPORINE	cyclosporine	CAPSULE;ORAL	065040	ANDA	American Health Packaging	68084-879-25	30 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-879-25) / 1 CAPSULE, GELATIN COATED in 1 BLISTER PACK (68084-879-95)	2015-09-30

Cyclosporine Drug Supply Chain Analysis

Last updated: February 19, 2026

This analysis details key suppliers and their roles in the pharmaceutical drug cyclosporine's supply chain, focusing on active pharmaceutical ingredient (API) manufacturing and formulation. The global cyclosporine market is characterized by established players and a consistent demand driven by its immunosuppressive and anti-inflammatory properties. Regulatory landscapes, particularly in the US and EU, dictate stringent quality and manufacturing standards for all suppliers.

What are the Primary Active Pharmaceutical Ingredient (API) Suppliers for Cyclosporine?

The production of cyclosporine API is concentrated among a limited number of manufacturers globally, primarily in Europe and Asia. These entities possess the specialized fermentation and purification capabilities required for this complex peptide.

• Novartis AG: As a pioneer in cyclosporine development (Sandimmune, Neoral), Novartis retains significant internal API manufacturing capacity. Its integrated supply chain is a critical component of its cyclosporine product offerings.
• Sandoz (a Novartis division): Sandoz, a leading global generic pharmaceutical company, is a major supplier of cyclosporine API and finished dosage forms. Sandoz operates multiple API manufacturing sites adhering to Good Manufacturing Practices (GMP).
• Fresenius Kabi: This German healthcare company is a significant producer of generic immunosuppressants, including cyclosporine API and finished products for intravenous and oral administration. Fresenius Kabi's supply chain is robust, serving a wide range of global markets.
• Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company, Dr. Reddy's manufactures and supplies cyclosporine API. Its presence in the generic market contributes to global supply diversity.
• Sun Pharmaceutical Industries Ltd.: India's largest pharmaceutical company is also a producer of cyclosporine API. Sun Pharma's extensive manufacturing network supports its global reach in supplying essential medicines.

These API suppliers operate under strict regulatory oversight from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Audits and compliance with current Good Manufacturing Practices (cGMP) are continuous requirements.

Who are the Key Formulators and Finished Dosage Form (FDF) Manufacturers?

Formulation and FDF manufacturing involve transforming the cyclosporine API into stable, bioavailable drug products. This stage requires specialized expertise in drug delivery systems and sterile manufacturing for injectable forms.

• Novartis AG: Continues to be a dominant player with its branded cyclosporine products (e.g., Sandimmune, Neoral, Restasis for ophthalmic use). Novartis controls its formulation and packaging through its global manufacturing network.
• Sandoz: As mentioned, Sandoz produces a wide range of generic cyclosporine capsules, solutions, and injectable formulations. Their FDF manufacturing sites are strategically located to serve major pharmaceutical markets.
• Fresenius Kabi: Specializes in intravenous (IV) cyclosporine formulations, critical for transplant patients and those requiring parenteral administration. They also produce oral dosage forms.
• Bausch Health Companies Inc.: Primarily known for its ophthalmic cyclosporine (Restasis was developed by Allergan, now part of AbbVie, but Bausch Health has generic and other ophthalmic formulations). Their focus is on eye care products.
• Hikma Pharmaceuticals PLC: A multinational pharmaceutical company that manufactures and markets a broad range of generic injectable and oral medications, including cyclosporine. Hikma's FDF production serves the US, Europe, and other international markets.
• Teva Pharmaceutical Industries Ltd.: A global leader in generic pharmaceuticals, Teva offers cyclosporine capsules and other formulations. Teva's extensive distribution network ensures broad market access.
• Viatris Inc.: Formed by the merger of Mylan and Pfizer's Upjohn business, Viatris is a significant supplier of generic pharmaceuticals, including cyclosporine oral and injectable products.

The formulation process for cyclosporine is complex due to its low solubility. This necessitates specific excipients and manufacturing techniques, such as microemulsion technology for oral solutions (like Neoral), to ensure consistent absorption.

What are the Regulatory Considerations Affecting Cyclosporine Supply?

The supply chain for cyclosporine is heavily influenced by stringent regulatory requirements to ensure drug safety, efficacy, and quality.

• FDA (U.S. Food and Drug Administration): All API and FDF manufacturers supplying to the U.S. market must comply with FDA cGMP regulations. This includes facility inspections, process validation, and robust quality control systems. Drug Master Files (DMFs) are typically submitted by API manufacturers.
• EMA (European Medicines Agency): Similar to the FDA, the EMA enforces strict GMP standards through its member states' national competent authorities. Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP) are often required for APIs.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use provides global standards for quality, safety, and efficacy, which are adopted by major regulatory bodies. This includes guidelines on impurities, stability testing, and validation.
• Pharmacopoeial Standards: Cyclosporine products must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define purity, assay, and other critical quality attributes.
• Supply Chain Security: Regulations are increasingly focusing on supply chain integrity to prevent counterfeiting and ensure product traceability. Serialization and track-and-trace requirements are becoming mandatory in many jurisdictions.

What are the Key Trends Impacting Cyclosporine Supply?

Several market and technological trends influence the current and future supply of cyclosporine.

• Generic Competition: The patent expiry of originator cyclosporine products has led to significant generic competition, driving down prices and increasing the importance of cost-efficient API and FDF manufacturing.
• Emerging Markets Growth: Increased access to healthcare in developing economies is driving demand for essential medicines like cyclosporine.
• Biologics and Biosimil Competition: While cyclosporine is a small molecule, the rise of biologics in transplantation and autoimmune disease treatment can influence market dynamics. However, cyclosporine remains a cornerstone therapy in many indications.
• Quality and Compliance Scrutiny: Regulatory bodies are intensifying their focus on quality and compliance, particularly concerning API sourcing and foreign manufacturing facilities. Any quality lapse can lead to drug shortages and significant financial penalties.
• Supply Chain Resilience: Global events, such as pandemics and geopolitical instability, have highlighted the need for diversified and resilient supply chains. Companies are seeking to reduce reliance on single-source suppliers or geographic regions.

Who are the Primary Distributors and Logistics Providers?

Efficient distribution is crucial for ensuring timely access to cyclosporine, particularly for critically ill patients.

• Wholesalers: Large pharmaceutical wholesalers like AmerisourceBergen, Cardinal Health, and McKesson in the U.S., and Phoenix Pharma AG and Sanacorp in Europe, are primary conduits for distributing finished cyclosporine products to pharmacies and hospitals.
• Specialty Pharmacies: For certain cyclosporine formulations or specific patient populations (e.g., transplant centers), specialty pharmacies play a role in dispensing and patient support.
• Third-Party Logistics (3PL) Providers: Companies like Kuehne+Nagel, DHL Supply Chain, and DSV are engaged in the global transportation and warehousing of both API and finished products, adhering to cold chain requirements where applicable.
• Direct Distribution: Some manufacturers, particularly for hospital-administered injectables, may engage in direct distribution to large healthcare institutions.

What are the Manufacturing Technologies and Challenges?

Cyclosporine's manufacturing involves complex biotechnological processes and formulation challenges.

• Fermentation: Cyclosporine is a cyclic undecapeptide produced by fermentation of the fungus Tolypocladium inflatum. This bioprocess requires precise control of fermentation parameters, including nutrient media, temperature, pH, and aeration, to maximize yield and produce the desired molecule.
• Purification: Post-fermentation, extensive purification steps are required to isolate cyclosporine from the fermentation broth and remove impurities. This typically involves solvent extraction, chromatography, and crystallization. Achieving high purity (e.g., >98%) is critical.
• Formulation:
  • Solubility: Cyclosporine's poor water solubility is a major formulation challenge.
  • Bioavailability: Oral formulations require strategies to enhance absorption. Microemulsion systems, as used in Neoral, improve bioavailability by forming a stable oil-in-water emulsion in the gastrointestinal tract.
  • Injectable Formulations: Sterile parenteral formulations require precise control over pH, tonicity, and the absence of particulate matter. Solubilizing agents are often necessary.
• Quality Control: Rigorous analytical testing is performed at each stage of manufacturing, including API identification, assay, purity (related substances), heavy metals, and microbial limits. Finished product testing includes dissolution, content uniformity, and sterility for injectables.

Key Takeaways

The cyclosporine supply chain is dominated by a few major API manufacturers, primarily in Europe and Asia, with significant FDF production by both originator and generic companies. Regulatory compliance (FDA, EMA, cGMP) is paramount and drives quality standards across the entire chain. Generic competition, growing demand in emerging markets, and increasing focus on supply chain resilience are shaping market dynamics. Manufacturing complexities, particularly the fermentation of the API and the formulation of poorly soluble FDFs, necessitate specialized expertise and significant capital investment.

Frequently Asked Questions

1. What is the typical shelf life for cyclosporine API and finished products? Cyclosporine API generally has a shelf life of 2-3 years when stored under recommended conditions. Finished dosage forms (capsules, oral solutions, injectables) typically have shelf lives ranging from 18 months to 3 years, depending on the formulation and packaging, as determined by stability studies.

2. Are there any significant single-source API suppliers for cyclosporine that pose a supply risk? While a few companies hold a substantial share of the market, the presence of multiple established global manufacturers (e.g., Sandoz, Dr. Reddy's, Sun Pharma) for cyclosporine API mitigates the risk of a complete single-source dependency. However, any disruption at a major facility for any of these key suppliers can impact global availability.

3. What are the primary storage conditions required for cyclosporine API and finished products? Cyclosporine API and most finished oral formulations require storage at controlled room temperature (15-30°C or 59-86°F), protected from light. Injectable formulations may have specific temperature requirements, often requiring refrigeration (2-8°C or 36-46°F) and protection from light. Manufacturers provide detailed storage instructions in product labeling and technical datasheets.

4. How do regulatory differences between major markets (US vs. EU) affect the supply chain for cyclosporine? While both the US (FDA) and EU (EMA) have stringent GMP requirements, specific filing procedures (e.g., DMFs vs. CEPs), impurity limits, and inspection protocols can differ. Manufacturers must comply with the specific requirements of each target market, which can add complexity and cost to global supply operations.

5. What is the expected impact of ongoing quality control inspections on the cyclosporine supply chain? Increased regulatory scrutiny on quality control and manufacturing processes can lead to temporary supply disruptions if facilities fail inspections or require remediation. However, it ultimately enhances the reliability and safety of the cyclosporine supply by ensuring adherence to cGMP and pharmacopoeial standards. Manufacturers with robust quality systems are better positioned to navigate this environment.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [EMA Website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website] [4] United States Pharmacopeial Convention. (n.d.). USP–NF. Retrieved from [USP Website] [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from [EDQM Website] [6] Various Pharmaceutical Company Websites and Annual Reports (e.g., Novartis AG, Sandoz, Fresenius Kabi, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Viatris Inc.). Information accessed on company product portfolios and manufacturing capabilities. [7] Pharmaceutical Market Research Reports on Cyclosporine Market Trends and Key Players. (Specific reports are proprietary and not cited here).